论文部分内容阅读
促红细胞生成素(EPO)因其促进造血功能而广泛用于临床。近年来大量实验证实,大剂量EPO能够通过抗氧化应激、抗凋亡、抗炎症等效应发挥组织保护作用,但会产生血栓及高血压等不良反应,临床效果不佳。而促红细胞生成素衍生肽(HBSP)既保留了EPO的组织保护活性又无EPO的副作用,近年来备受关注。最新报道证实,HBSP通过抗凋亡、抗炎、抗氧化应激对神经系统、心脏、肾脏等发挥多种组织保护作用,具有良好的临床应用前景。
Erythropoietin (EPO) is widely used clinically for its hematopoietic function. In recent years, a large number of experiments confirmed that high-dose EPO can exert tissue protective effects such as anti-oxidative stress, anti-apoptosis, anti-inflammatory effects, but will produce adverse reactions such as thrombosis and hypertension, poor clinical outcomes. Erythropoietin-derived peptide (HBSP) has not only preserved the tissue protective activity of EPO but also has no side effects of EPO, and has drawn much attention in recent years. Recent reports confirm that HBSP exerts various tissue protective effects on the nervous system, heart and kidney through anti-apoptotic, anti-inflammatory and anti-oxidative stress and has good clinical application prospects.